Bio Saga Headlines

Bio Saga

Tuesday, June 23, 2015

Protein modeling & Drug discovery training and Internship


We are bringing out a special program, due to huge no of enquirers and considering a special
demand by all to conduct a special batch of training on following topic

Area of training/Internship

Protein modeling & Drug discovery



Start date - 15th July


Emerging trend in healthcare and drug development is being appreciated and this success is being sound after a long dedicated research work on drug discovery, modeling & simulation. If you are giving a thought on finding novel drug, new molecules, we are here to help you. RASA has been very keen to give your research work a novel touch, providing few advanced skill set to you within a framed syllabus designed for you. 
 





What will you learn?

·        Give inside how receptor binds to ligand.
·        Help to find ligand activity.
·        Useful in structure based discovery.
·        Can do protein-protein interaction
·        Know more about protein-ligand interaction.
·        Hands on training on Gromacs right from installation to modeling and stimulation.
·        Contain both bioinformatics and chemo-informatics portion.
·        Good for who are looking to build career in chemical
·        Inside how protein behaves when surrounded by water.
·        E.g. Protein and ligand interaction in hydrophilic condition.
·        Docking will be performed by using Autovina.

Training features:

1) We have combined 2- 3 different Industrial training module to give you extra ordinary exposure within a limited period along with your projects

2) Selected courses are having free module as summer special additional training.

3) We are giving you a mini project to explore your learning and knowledge of entire training that will make you an independent learner and will make you ready for job.

4) Rasa Summer training will help you to build up your logic which will lead to develop new scientific ideas beyond your proximity
  
Duration: 1 month (Training +Project)
Last date for early bird registration
25th June
Early bird discount will be awarded
Registration deadline
6st July
15 Seat (on first come first serve basis )

Thursday, April 30, 2015

Intel Offers Access to Optimized Versions of Open-source Solutions for Life Sciences Space

At the Bio-IT World Conference last week, Intel unveiled a new website, dubbed Optimized Code, that offers access to versions of several popular open-source bioinformatics analysis tools that the company has optimized to run on Intel Xeon processors, with the aim of generating results faster and more efficiently than standard iterations of these solutions.


The first set of applications that the company has released specifically for genomic analysis include optimized versions of  the Broad Institute's Genome Analysis Toolkit; Blast algorithms for nucleotide- and protein-based sequence searching; BWA-ALN, software for mapping low-divergent sequences to a reference genome; and MPI-HMMER, protein sequence analysis software. The company has also released optimized code for AMBER and NAMD, both of which are used for simulating the molecular dynamics of biomolecular systems. The Intel website provides performance numbers for each of the optimized codes as well as directions for how to access and download the tools.


Do you wish to know more?

Thursday, February 19, 2015

PerkinElmer, Waters Team on Chromatography Products

PerkinElmer announced yesterday that it has signed an agreement with Waters to offer solutions combing the firm's chromatography instruments and software.

Under the agreement, PerkinElmer's liquid and gas chromatography portfolio will be standardized on Waters' Empower Software, which is used to manage multi-vendor chromatography data, simplifying data collection, processing, and reporting. 
PerkinElmer said this standardization will enable its customers to simplify their workflows by unifying their chromatography data onto one platform.

It also said that it anticipates the alliance with Waters will lead to new product launches in the environmental, industrial, and applied markets.

Financial and other terms of the agreement were not disclosed.

Monday, September 22, 2014

Merck KGaA to Buy Sigma-Aldrich for $17B

Merck KGaA today announced that it will acquire Sigma-Aldrich for $17 billion.
Under the terms of the agreement, Merck will acquire all outstanding shares of Sigma-Aldrich for $140 per share, which would represent a 37 percent premium to Sigma-Aldrich's closing stock price of $102.37 on Sept. 19. The deal is anticipated to be immediately accretive to Merck's EPS pre and EBITDA margin, the companies said, and Merck anticipates achieving annual synergies of about €260 million ($334 million) within three years after the completion of the acquisition.

In a statement, Merck KGaA Chairman Karl-Ludwig Kley called the deal a "quantum leap" for the company's life science business, whose contributions to the German firm's overall earnings would more than double with the addition of Sigma-Aldrich.

"In one of the world's key industries two companies that fit perfectly together have found each other to present a much broader product offering to our global customers in research, pharma, and biopharma manufacturing, and diagnostic and testing labs," he said.
The deal, he added, "will secure stable growth and profitability in an industry that is driven by trends, such as the globalization of research and manufacturing. What's more, the combination gives us the possibility to invest even more in innovation going forward."
St. Louis-based Sigma-Aldrich develops and manufactures a wide range of life science products, including chemicals, biochemicals, and equipment for life science research ¬– including studies directed at genomic and proteomic research – as well as biotech and pharma development. The company was founded in 1951 and has about 9,000 employees.
In the omics-related life science tools space, Merck KGaA's purchase of Sigma-Aldrich would represent the largest transaction in several years, surpassing Thermo Fisher Scientific 's buy of Life Technologies for $13.6 billion earlier this year.

In a note, ISI Group analyst Ross Muken said that although he sees the newly combined firm as a "more formidable competitor to Thermo Fisher in base reagents/chemicals, we think that the new entity still lacks Thermo Fisher's breadth of offering given a lack of foothold in instrumentation."

Sigma-Aldrich President and CEO Rakesh Sachdev said the combined firms "will be well-positioned to deliver significant customer benefits, including a broader, complementary range of products and capabilities, greater investment in breakthrough innovations, enhanced customer service, and a leading e-commerce and distribution platform in the industry."

The companies said that in the laboratory and academia markets, the combined firm will provide customers a complementary range of products across laboratory chemicals, biologics, and reagents, while in pharma and biopharma production, Sigma-Aldrich will complement Merck KGaA business EMD Millipore's existing products and capabilities "with additions along the entire value chain of drug production and validation." Furthermore, the deal is anticipated to expand Merck EMD Millipore's global reach by increasing its presence in North America and expanding its exposure to Asia.

In 2013, Sigma-Aldrich recorded $2.70 billion in revenues and a profit of $491 million, or $4.06 per share. Merck KGaA had €11.10 billion in sales last year with net income of €1.20 billion, or €2.77 per share.

Merck KGaA will pay for the purchase through a combination of cash, bank loans, and bonds. It has secured bridge financing for the deal, which is expected to close in mid-2015.
Mizuho Securities analyst Peter Lawson in a note today that the deal "seems like a natural fit to us and takes Merck [KGaA] deeper into biology, with the Sigma business fitting well with Merck’s legacy chemical businesses and the acquired Millipore business. We see the potential for competitive bids as low based upon a high-end multiple, and only see a handful of other potential suitors."

Shares of Sigma-Aldrich rose nearly 34 percent in trading Monday morning on the Nasdaq to $136.71.

Tuesday, June 3, 2014

Roche Acquires Nanopore Sequencing Firm Genia Technologies for up to $350M & Sequenom Sells Bioscience Business to Agena for $31.8M

Roche said today that it will acquire Genia Technologies for $125 million in cash and up to $225 million in additional payments tied to milestones. Once the deal closes, Genia will be integrated into the Roche Sequencing Unit.

Genia, based in Mountain View, Calif., has been developing a single-molecule sequencing-by-synthesis technology that uses nanopore-based electrical detection and employs a semiconductor integrated circuit.

Last fall, Genia and its academic collaborators at Columbia University, Harvard University, and the National Institute of Standards and Technology published proof of concept for their NanoTag sequencing technology.

According to Roche, Genia's technology "is expected to reduce the price of sequencing while increasing speed and sensitivity."

Roche has also been working with Pacific Biosciences on developing a sequencing system and assays for clinical diagnostics using PacBio's single-molecule real-time sequencing technology. Last fall, the two companies penned an agreement under which Roche paid PacBio $35 million upfront and could pay up to an additional $40 million in milestones.

Roche first stepped into the next-generation sequencing arena when it acquired 454 Life Sciences in 2007 for $155 million in cash and stock, but it decided last year to phase out that technology by mid-2016.

The company also had research and development partnerships with IBM and DNA Electronics to develop new sequencing technology but discontinued those projects last year.
___________________________________________________________________________________

Sequenom said after the close of the market Friday that it has sold its bioscience business, which includes its MassArray system, to Agena Bioscience for $31.8 million.

Sequenom had said in September that it would conduct a strategic review for the business, formerly called the Genetic Analysis segment, but at the time didn't offer details on the reason for seeking a potential sell off.

"This sale strengthens our balance sheet, and will enable us to focus exclusively on our Sequenom Laboratories business as we work toward achieving profitability," Sequenom Chairman and CEO Harry Hixson said in a statement today.

Sequenom's sales have been increasingly driven by its Sequenom Laboratories business, and in particular its MaterniT21 Plus noninvasive prenatal test for fetal aneuploidy. It recently reported a 20 percent year-over-year increase for its first quarter revenues.

The bioscience business' flagship product is the MassArray system, a mass spectrometry-based platform for measuring genetic target material and variations. It also includes Sequenom's iPlex assay for analyzing multiplex SNPs and somatic mutations.

Agena, a San Diego-based portfolio company of investment firm Telegraph Hill Partners, will pay $31.8 million, but may pay an additional $4 million in contingent consideration based on certain regulatory and sales milestones. It also has assumed certain liabilities of the bioscience business and has taken over the facility lease for that business. Agena also said that it will offer employment to all of the employees of the bioscience business.

Agena also intends to file for US Food and Drug Administration clearance of the MassArray platform with the IMPACT Dx System, for which Sequenom filed a 510(k) application last year.
Piper Jaffray Senior Research Analyst William Quirk pointed out in a research note that the selling price for the bioscience business was below its FY 2013 revenues of $42.9 million and represents a discount from historical diagnostic/life science tools M&A transactions, which generally run around 2x revenues.

"We are encouraged with Sequenom focusing resources in higher margin products (NIPT testing), although we are surprised with the ultimate selling price of the Bioscience business," Quirk said.
In Monday morning trade on the Nasdaq, shares of Sequenom were down 1 percent at $3.03.

Life Science and Informatics

What is this?
is this a new industry?
or a old wine in a new bottle?

Well Life Sciences and Informatics can be anything form computational biology, all omes and omics, core bioinformatics to curation and literature mining, database creation, in the area of biology, chemistry , bio-chem space.

There are number of companies in India and bangalore is the forefront as a major bio-cluster with 20 to 30 companies in this sphere.

now how good are these companies doing?
how good are they in terms of the international markets and how profitable is their business?
what do they do?
their clients?

These are some interesting things that could be discussed in this blog page...

Tag It